A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR+/HER2+ advanced ...

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, ...

Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has announced that the ...

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare ...

Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic ...

Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.

Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.